Vascular Biogenics (NASDAQ:VBLT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Vascular Biogenics (NASDAQ:VBLT – Get Rating) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Fidelity Earnings reports. Vascular Biogenics had a negative return on equity of 63.08% and a negative net margin of 3,895.83%. During the same period last year, the company earned ($0.12) EPS.

Shares of NASDAQ VBLT opened at $1.57 on Thursday. Vascular Biogenics has a 52-week low of $1.10 and a 52-week high of $3.04. The firm has a fifty day moving average of $1.54 and a 200-day moving average of $1.72.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp purchased a new stake in shares of Vascular Biogenics during the 4th quarter valued at $89,000. Millennium Management LLC purchased a new stake in Vascular Biogenics during the 2nd quarter worth $89,000. Geode Capital Management LLC boosted its position in Vascular Biogenics by 62.1% during the 3rd quarter. Geode Capital Management LLC now owns 40,323 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 15,450 shares during the period. Advisor Group Holdings Inc. boosted its position in Vascular Biogenics by 49.2% during the 1st quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 12,133 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new stake in Vascular Biogenics during the 1st quarter worth $64,000. 26.15% of the stock is owned by institutional investors.

Several brokerages recently issued reports on VBLT. StockNews.com began coverage on Vascular Biogenics in a research report on Sunday. They set a “hold” rating for the company. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. Finally, Chardan Capital began coverage on Vascular Biogenics in a report on Thursday, April 28th. They issued a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vascular Biogenics has a consensus rating of “Hold” and an average price target of $4.56.

About Vascular Biogenics (Get Rating)

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications.

Featured Articles